RxDoctor Payments Data

Jaylon Snyder, PA

Surgical · Allentown, PANPI 1427726991

Payments from drug & device makers

$665in general payments, 2019–2025

Across 28 payments — averaging $23.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$243
  • AstraZeneca$79
  • Blue Earth Diagnostics$69
  • Astellas Pharma US Inc$65
  • Myriad Genetic Laboratories, Inc.$59
  • Dendreon Pharmaceuticals LLC$52
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$60090%
  • Education$6510%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$665 in reported general payments places this provider in the 60th percentile of 626 surgical providers in Pennsylvania.

See all surgical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$84,200
Medicare patients
625
Services billed
2,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron71$54,312
GemtesaVibegron22$21,550
Trospium Chloride90$9,609
Tamsulosin Hcl369$7,627
Potassium Citrate ErPotassium Citrate59$4,474
Methenamine Hippurate24$2,997
Silodosin12$1,420
Finasteride89$1,166
Dutasteride13$1,110
Oxybutynin Chloride ErOxybutynin Chloride32$771
Alfuzosin Hcl ErAlfuzosin Hcl16$551
Cephalexin114$517
Oxybutynin Chloride13$422
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim166$413
Ketorolac Tromethamine16$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$65$54,31271 claims
Sumitomo Pharma America, Inc.Gemtesa$21$21,55022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 626 surgical providers in Pennsylvania.

Other surgical in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →